An interventional study of Early Carbapenem de-escalation in Anti-Bacterial Agents, sponsored by Chiang Mai University. Completed. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2017-04-19.
Sponsored by Chiang Mai University · Not applicable, Interventional, and Health services research
Early de-escalation of carbapenems can reduce unnecessary use of carbaepenems compared with late de-escalation without compromised clinical outcomes
A cluster randomized control trial was conducted among patients receiving care at the medicine units of the Maharaj Nakorn Chiang Mai Hospital.
Patients were randomly assigned into 2 groups. The standard group followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team. The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
Clinical outcomes included rate of de-escalation within the first 24 hour, the mortality rate, and other clinical outcomes.
Chiang Mai University is the lead sponsor of 116 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria
De-escalation carbapenems within 24 hours or no later than 72 hours of prescription by Infectious disease specialist (early de-escalation).
Other: Early Carbapenem de-escalation
De-escalation followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team
The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
The rate of de-escalation within the first 24 hour
Compare the rate of de-escalation within the first 24 hour between arm 1 and arm 2
Time frame: 24 hours
Mortality rate
Compare the mortality rate between 2 groups
Time frame: 90 days
Readmission within 30 days,
Compare the rate of readmission within 30 days between 2 groups
Time frame: 30 days
Costs of carbapenems
Compare the cost of carbapenem prescription between 2 groups
Time frame: 30 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chiang Mai University